• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MacroGenics Inc. (Amendment)

    2/13/24 5:08:11 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MGNX alert in real time by email
    SC 13G/A 1 tv01383-macrogenicsinc.htm SCHEDULE 13G/A macrogenicsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  MacroGenics Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  556099109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  556099109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    49,317

    7.  SOLE DISPOSITIVE POWER

    4,235,304

    8.  SHARED DISPOSITIVE POWER

    74,090

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,309,394

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.95%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    MacroGenics Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    9704 Medical Center Drive
    Rockville, MD 20850-3368

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    556099109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $MGNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGNX

    DatePrice TargetRatingAnalyst
    11/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/1/2024Buy → Neutral
    BTIG Research
    7/31/2024$18.00 → $5.00Buy → Neutral
    B. Riley Securities
    7/31/2024Buy → Neutral
    Guggenheim
    5/10/2024$24.00 → $8.00Outperform → Market Perform
    BMO Capital Markets
    5/10/2024$29.00 → $7.00Buy → Hold
    Stifel
    5/10/2024Buy → Hold
    TD Cowen
    4/26/2024$25.00Buy
    B. Riley Securities
    More analyst ratings

    $MGNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MacroGenics Announces Date of First Quarter 2025 Financial Results

      ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future. About MacroGenics, Inc.MacroGenics (the Company) is a biopharm

      5/6/25 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics to Participate in Upcoming Investor Conference

      ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month: The Citizens Life Sciences Conference (New York). Members of MacroGenics' management team will participate in a fireside chat on Thursday, May 8, 2025, at 10:30am ET. Management will also participate in one-on-one meetings. A webcast of the above presentation may be accessed under "Events & Presentations" in the Invest

      5/1/25 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

      Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical com

      3/20/25 4:02:38 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr VP, Research & CSO Bonvini Ezio converted options into 16,665 shares, increasing direct ownership by 15% to 124,414 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:31:12 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, CFO and Secretary Karrels James converted options into 14,998 shares and covered exercise/tax liability with 5,790 shares (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:29:59 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Koenig Scott converted options into 42,329 shares, increasing direct ownership by 6% to 777,415 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      2/19/25 4:28:50 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    Financials

    Live finance-specific insights

    See more
    • MacroGenics Announces Date of First Quarter 2025 Financial Results

      ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025.  The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended March 31, 2025. The Company may resume its practice of hosting quarterly results conference calls in the future. About MacroGenics, Inc.MacroGenics (the Company) is a biopharm

      5/6/25 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

      Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase 2 study of lorigerlimab in ovarian cancerAdvancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028 and MGC030Discontinuing further internal clinical development of vobra duo; exploring potential partneringCash, cash equivalents and marketable securities of $201.7 million as of December 31, 2024; cash runway extended into the second half of 2026Conference call scheduled for today at 4:30 p.m. ET  ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical com

      3/20/25 4:02:38 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call

      ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET Conference Call Information To participate via telephone, please register in advance via this link. Upon registration, all telephone part

      3/6/25 7:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by MacroGenics Inc.

      SC 13G - MACROGENICS INC (0001125345) (Subject)

      11/20/24 10:44:27 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

      SC 13G/A - MACROGENICS INC (0001125345) (Subject)

      11/14/24 5:13:06 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by MacroGenics Inc.

      SC 13G - MACROGENICS INC (0001125345) (Subject)

      6/4/24 4:53:11 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    Leadership Updates

    Live Leadership Updates

    See more
    • MacroGenics Announces Leadership Transition

      Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company's Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the t

      10/30/24 7:30:00 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

      ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu will serve as a member of MacroGenics' Science and Technology Committee and Ms. Karson will serve as a member of the Company's Audit Committee. Following the appointment of Dr. Liu and Ms. Karson, MacroGenics' Board will comprise ten directors, nine of whom are independent. "We are delighted to have both Margaret and Meenu join Ma

      1/4/23 4:30:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Announces Appointment of William Heiden to Board of Directors

      ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors, effective May 22, 2022. Mr. Heiden will serve as Chair of the board and a member of the Audit Committee. Following the appointment of Mr. Heiden, the Board will comprise eight directors, seven of whom are independent. Mr. Heiden is replacing Paulo F. Costa as Chair. Mr. Costa served in the Chair position until his term as director expired on May 19, 2022.  "We are delighted to have Bill join Macr

      5/23/22 4:01:00 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MARGENZA issued to MACROGENICS INC

      Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

      5/29/23 4:45:45 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for MARGENZA

      Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:

      12/20/20 4:31:01 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by MacroGenics Inc.

      DEFA14A - MACROGENICS INC (0001125345) (Filer)

      4/11/25 4:01:29 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by MacroGenics Inc.

      DEF 14A - MACROGENICS INC (0001125345) (Filer)

      4/11/25 4:00:50 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MACROGENICS INC (0001125345) (Filer)

      3/20/25 4:05:47 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Target N V bought $669,585 worth of shares (150,000 units at $4.46), increasing direct ownership by 2% to 9,929,963 units (SEC Form 4)

      4 - MACROGENICS INC (0001125345) (Issuer)

      10/4/23 3:31:17 PM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MacroGenics downgraded by JMP Securities

      JMP Securities downgraded MacroGenics from Mkt Outperform to Mkt Perform

      11/7/24 6:29:13 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by BTIG Research

      BTIG Research downgraded MacroGenics from Buy to Neutral

      8/1/24 6:28:50 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MacroGenics downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded MacroGenics from Buy to Neutral and set a new price target of $5.00 from $18.00 previously

      7/31/24 6:30:32 AM ET
      $MGNX
      Biotechnology: Pharmaceutical Preparations
      Health Care